-
1Academic Journal
Συγγραφείς: A. V. Aboleshina, А. В. Аболешина
Συνεισφορές: Работа выполнена в рамках фундаментальной научной тематики FURS-2022-008 «Разработка персонализированной программы лечения рефрактерного ревматоидного артрита на основе изучения молекулярно-генетических и молекулярно-биологических предикторов. Создание и апробация регистра пациентов с ревматоидным артритом, резистентных к базисной противовоспалительной терапии» (номер государственного задания 1021051503137-7).
Πηγή: Rheumatology Science and Practice; Vol 62, No 5 (2024); 494-500 ; Научно-практическая ревматология; Vol 62, No 5 (2024); 494-500 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: комплексная гериатрическая оценка, elderly age, multimorbidity, polypharmacy, geriatric syndromes, comprehensive geriatric assessment, пожилой возраст, мультиморбидность, полипрагмазия, гериатрические синдромы
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3635/2403; Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2020.; GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594-e610. doi:10.1016/S2665-9913(23)00211-4; Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: A systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463-1471. doi:10.1136/annrheumdis-2019-215920; Зинчук ИЮ, Амирджанова ВН. Социальное бремя ревматоидного артрита. Научно-практическая ревматология. 2014;52(3):331-335.; Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;46(1):32-39.; Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States. Arthritis Rheum. 2003;48:917-926. doi:10.1002/art.10897; Балабанова РМ, Эрдес ШФ. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000–2010 гг. Научно-практическая ревматология. 2012;50(3):10-12.; Dyussenbayev A. Age periods of human life. Adv Soc Sci Res J. 2017;4(6):258-263. doi:10.14738/assrj.46.2924; WHO global strategy and action plan on ageing and health (2016– 2020). http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_17-en.pdf (Accessed: 8th August 2024).; Kobak S, Bes C. An autumn tale: Geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(1):3-11. doi:10.1177/1759720X17740075; Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, et al. Polypharmacy is associated with treatment response and serious adverse events: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2019;58(10):1767-1776. doi:10.1093/rheumatology/kez037; Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: A meta-analysis. JAMA. 2010;304(4):443-451. doi:10.1001/jama.2010.1013; Innala L, Berglin E, Möller B, Ljung L, Smedby T, Södergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study. Arthritis Res Ther. 2014;16(2):R94. doi:10.1186/ar4540; Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, et al. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2019;22(6):1084-1093. doi:10.1111/1756-185X.13428; Tan TC, Gao X, Thong BY, Leong KP, Lian TY, Law WG, et al.; TTSH Rheumatoid Arthritis Study Group. Comparison of elderlyand young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis. 2017;20(6):737-745. doi:10.1111/1756-185X.12861; Li X, Cesta A, Movahedi M, Bombardier C. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: Results from the Ontario Best Practices Research Initiative. Arthrit Res Ther. 2022;24(1):255. doi:10.1186/s13075-022-02952-1; Romão VC, Humby F, Kelly S, Di Cicco M, Mahto A, Lazarou I, et al. Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: Findings from a prospective observational longitudinal early arthritis cohort study. Semin Arthritis Rheum. 2020;50(4):735-743. doi:10.1016/j.semarthrit.2020.03.018; Zhang JF, Ye XL, Duan M, Zhou XL, Yao ZZ, Zhao JX. [Clinical characteristics of elderly and younger onset rheumatoid arthritis. Zhonghua Yi Xue Za Zhi. 2020;100(47):3788-3792 (In Chinese). doi:10.3760/cma.j.cn112137-20200506-01439; Huscher D, Sengler C, Gromnica-Ihle E, Bischoff S, Eidner T, Ochs W, et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: A matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol. 2013;31(2):256-262.; Lahaye C, Tatar Z, Dubost J-J, Tournadre A, Soubrier M. Management of inflammatory rheumatic conditions in the elderly. Rheumatology (Oxford). 2019;58:748-764.; Сатыбалдыев АМ, Демидова НВ, Гриднева ГИ, Никишина НЮ, Герасимова ЕВ, Гукасян ДА, и др. Клиническая характеристика трех когорт раннего ревматоидного артрита с поздним началом (в возрасте 50 лет и старше). Обобщение 40-летнего опыта. Научно-практическая ревматология. 2020;58(2):140-146.; Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, et al.; CATCH Investigators. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology (Oxford). 2014;53(6):1075-1086. doi:10.1093/rheumatology/ket449; van der Heijde DM, van Riel PL, van Leeuwen MA, van’t Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: Results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol. 1991;18(9):1285-1289.; Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J; SCQM physicians. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford). 2014;53(4):671-677. doi:10.1093/rheumatology/ket399; Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol. 2019;10:2247. doi:10.3389/fimmu.2019.02247; Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254. doi:10.1111/j.1749-6632.2000.tb06651.x; Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes? Front Immunol. 2018;8:1960. doi:10.3389/fimmu.2017.01960; Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(10):604-613. doi:10.1038/nrrheum.2013.92; Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity – catalysts of autoimmunity and chronic inflammation. Arthr Res Ther. 2003;5:225-234. doi:10.1186/ar974; Chalan P, Van den Berg A, Kroesen B, Brouwer L, Boots A. Rheumatoid arthritis, immunosenescence and the hallmarks of aging. Curr Aging Sci. 2015;8:131-146. doi:10.2174/1874609808666150727110744; Lindstrom T, Robinson W. Rheumatoid arthritis: A role for immunosenescence? J Am Geriatr Soc. 2010;58:1565-1575. doi:10.1111/j.1532-5415.2010. 02965.x; Weyand CM, Yang Z, Goronzy JJ. T-cell aging in rheumatoid arthritis. Curr Opin Rheumatol. 2014;26(1):93-100. doi:10.1097/BOR.0000000000000011; Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14(12):877-782. doi:10.1016/j.jamda.2013.05.009; Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403-440. doi:10.1210/er.2007-0038; Weyand C, Goronzy J. Aging of the immune system. Annals ATS. 2016;13:422-428. doi:10.1513/AnnalsATS.201602-095AW; Chen JM, Cui GH, Jiang GX, Xu RF, Tang HD, Wang G, et al. Cognitive impairment among elderly individuals in Shanghai suburb, China: Association of C-reactive protein and its interactions with other relevant factors. Am J Alzheimers Dis Other Demen. 2014;29(8):712-717. doi:10.1177/1533317514534758; Van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskeletal Disorders. 2016;17:184. doi:10.1186/s12891-016-1038-3; Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: Results from the Ontario Best Practices Research Initiative. Clin Rheumatol. 2016;35(3):759-763. doi:10.1007/s10067-015-3031-x; Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-68. doi:10.1136/annrheumdis-2013-204223; Baghdadi L, Woodman R, Shanahan E, Mangoni A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2015;10:e0117952. doi:10.1371/journal.pone; Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):183. doi:10.1186/s13075-016-1077-z; Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:469-483. doi:10.1016/j.berh.2011.10.009; Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489. doi:10.1136/annrheumdis-2014-206624; Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: A Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929-934. doi:10.1136/ard.2010.143396; Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53-61. doi:10.1093/rheumatology/kes305; Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-1136. doi:10.1136/annrheumdis-2016-210708; Simon T, Thompson A, Gandhi K, Hochberg M, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis. Arthr Res Ther. 2015;17:212. doi:10.1186/s13075-015-0728-9; Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: The impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415-421. doi:10.1136/annrheumdis-2013-204021; Maassen JM, Bergstra SA, Chopra A, Govind N, Murphy EA, Vega-Morales D, et al. Phenotype and treatment of elderly onset compared with younger onset rheumatoid arthritis patients in international daily practice. Rheumatology (Oxford). 2021;60(10):4801-4810. doi:10.1093/rheumatology/keab102; Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. doi:10.1136/annrheumdis-2016-210715; Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26. doi:10.1002/art.39480; Tkacheva ON, Runikhina NK, Ostapenko VS, Sharashkina NV, Mkhitaryan EA, Onuchina JS, et al. Prevalence of geriatric syndromes among people aged 65 years and older at four community clinics in Moscow. Clin Interv Aging. 2018;13:251-259. doi:10.2147/CIA.S153389; Niksolat F, Zandieh Z, Roshani F, Larijani SS, Mirfakhraee H, Bahadori F, et al. Geriatric syndromes among patients with rheumatoid arthritis: A comparison between young and elderly patients. Ethiop J Health Sci. 2022;32(4):791-798. doi:10.4314/ejhs.v32i4.16; Ward KT, Reuben DB. Comprehensive geriatric assessment. URL: https://www.uptodate.com/contents/comprehensive-geriatric-assessment (Accessed: 25th July 2024).; Van Moerbeke A, Magdelijns F, Cleutjens F, Boonen A, van Onna M. Development and evaluation of a clinic for elderly patients with rheumatoid arthritis and multimorbidity: A pilot study. ACR Open Rheum J. 2021;3:34-40. doi:10.1002/acr2.11213; van Leendert JAA, Linkens AEMJH, Poeze M, Pijpers E, Magdelijns F, Ten Broeke RHM, et al. Mortality in hip fracture patients after implementation of a nurse practitioner-led orthogeriatric care program: Results of a 1-year follow-up. Age Ageing. 2021;50(5):1744-1750. doi:10.1093/ageing/afab031; Radner H, Yoshida K, Smolen JS, Solomon DH. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheum. 2014;10:252-256. doi:10.1038/nrrheum.2013.212; Jogerst GJ. Geriatrics assessment is not just for geriatricians. Advances in Gerontology. 2006;19:120-128.; Kastner M, Hayden L, Wong G, Lai Y, Makarski J, Treister V, et al. Underlying mechanisms of complex interventions addressing the care of older adults with multimorbidity: A realist review. BMJ Open. 2019;9(4):e025009. doi:10.1136/bmjopen-2018-025009
-
2
-
3Academic Journal
Συγγραφείς: O. Tkacheva N., Yu. Kotovskaya V., N. Runikhina K., E. Frolova V., V. Ostapenko S., N. Sharashkina V., E. Baranova I., S. Bulgakova V., S. Villevalde V., D. Duplyakov V., A. Ilnitskiy N., O. Kislyak A., Zh. Kobalava D., A. Konradi O., S. Nedogoda V., Ya. Orlova A., N. Pogosova V., K. Proshchaev I., G. Chumakova A., О. Ткачева Н., Ю. Котовская В., Н. Рунихина К., Е. Фролова В., В. Остапенко С., Н. Шарашкина В., Е. Баранова И., С. Булгакова В., С. Виллевальде В., Д. Дупляков В., А. Ильницкий Н., О. Кисляк А., Ж. Кобалава Д., А. Конради О., С. Недогода В., Я. Орлова А., Н. Погосова В., К. Прощаев И., Г. Чумакова А.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 642-661 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 642-661 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: aging, senile asthenia, arterial hypertension, autonomy, complex geriatric assessment, старение, старческая астения, артериальная гипертония, автономность, комплексная гериатрическая оценка
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2517/2204; Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-10. DOI:10.1001/jama.287.8.1003.; Федеральная служба государственной статистики. Демография [Цитировано 14.04.2021]. Доступно на: https://rosstat.gov.ru/folder/12781.; Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58:1791-6. DOI:10.1111/j.1532-5415.2010.03032.x.; van der Cammen TJ, Rajkumar C, Onder G, et al. Drug cessation in complex older adults: time for action. Age Ageing. 2014;43:20-5. DOI:10.1093/ageing/aft166.; Mitchell GF, Lacourciere Y, Ouellet JP, et al. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation. 2003;108:1592-8. DOI:10.1161/01.CIR.0000093435.04334.1F.; Boddaert J, Tamim H, Verny M, Belmin J. Arterial stiffness is associated with orthostatic hypotension in elderly subjects with history of falls. J Am Geriatr Soc. 2004;52:568-72. DOI:10.1111/j.1532- 5415.2004.52163.x.; Agnoletti D, Valbusa F, Labat C, et al.; PARTAGE Study Investigators. Evidence for a prognostic role of orthostatic hypertension on survival in a very old institutionalized population. Hypertension. 2016;67:191-6. DOI:10.1161/HYPERTENSIONAHA.115.06386.; Sung J, Choi SH, Choi YH, et al. The relationship between arterial stiffness and increase in blood pressure during exercise in normotensive persons. J Hypertens. 2012;30:587-91. DOI:10.1097/HJH.0b013e32834f41b1.; Uetani E, Tabara Y, Igase M, et al. Postprandial hypertension, an overlooked risk marker for arteriosclerosis. Atherosclerosis. 2012;224:500-5. DOI:10.1016/j.atherosclerosis.2012.07.015.; Liu YP, Gu YM, Thijs L, et al. Do level and variability of systolic blood pressure predict arterial properties or vice versa? J Hum Hypertens. 2014;28:316-22. DOI:10.1038/jhh.2013.106.; Angelousi A, Girerd N, Benetos A, et al. Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis. J Hypertens. 2014;32:1562-71. DOI:10.1097/HJH.0000000000000235.; Mol A, Bui Hoang PTS, Sharmin S, et al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2019;20(5):589-97.e5. DOI:10.1016/j.jamda.2018.11.003.; Lipsitz LA. A 91-year-old woman with difficult-to-control hypertension: a clinical review. JAMA. 2013;310:1274-80. DOI:10.1001/jama.2013.277027.; Khattar RS, Swales JD, Dore C, et al. Effect of aging on the prognostic significance of ambulatory systolic, diastolic, and pulse pressure in essential hypertension. Circulation. 2001;104:783-9. DOI:10.1161/hc3201.094227.; Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019;124(7):1045-60. DOI:10.1161/CIRCRESAHA.118.313236.; Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. DOI:10.1016/S0140-6736(02)11911-8.; Zhang WB, Pincus Z. Predicting all-cause mortality from basic physiology in the Framingham Heart Study. Aging Cell. 2016;15:39-48. DOI:10.1111/acel.12408.; Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138:353-64. DOI:10.1093/oxfordjournals.aje.a116868.; Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487-99. DOI:10.1016/S1474-4422(05)70141-1.; Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55. DOI:10.1016/s0197-4580(00)00096-8.; Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-5. DOI:10.1016/s0140-6736(96)90608-x.; Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999;53:1948-52. DOI:10.1212/wnl.53.9.1948.; Baumgart M, Snyder HM, Carrillo MC, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11:718-26. DOI:10.1016/j.jalz.2015.05.016.; Walker KA, Sharrett AR, Wu A, et al. Association of Midlife to Late-Life Blood Pressure Patterns. JAMA. 2019;322(6):535-45.; Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ. 1989;298:1356-7.; van Hateren KJ, Landman GW, Kleefstra N, et al. Lower blood pressure associated with higher mortality in elderly diabetic patients (ZODIAC-12). Age Ageing. 2010;39:603-9. DOI:10.1093/ageing/afq080.; Ronnback M, Isomaa B, Fagerudd J, et al.; Botnia Study Group. Complex relationship between blood pressure and mortality in type 2 diabetic patients: a follow-up of the Botnia Study. Hypertension. 2006;47:168-73. DOI:10.1161/01.HYP.0000199667.30253.b7.; Boshuizen HC, Izaks GJ, van Buuren S, Ligthart GJ. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ. 1998;316:1780-4. DOI:10.1136/bmj.316.7147.1780.; Satish S, Zhang DD, Goodwin JS. Clinical significance of falling blood pressure among older adults. J Clin Epidemiol. 2001;54:961-7.; Rogers MA, Ward K, Gure TR, et al. Blood pressure trajectories prior to death in patients with diabetes. Diabetes Care. 2011;34:1534-39. DOI:10.2337/dc11-0441.; Benetos A, Gautier S, Labat C, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study. J Am Coll Cardiol. 2012;60:1503-11. DOI:10.1016/j.jacc.2012.04.055.; Aparicio LS, Thijs L, Boggia J, et al.; International Database on Home Blood Pressure in Relation to Cardiovascular Outcome (IDHOCO) Investigators. Defining thresholds for home blood pressure monitoring in octogenarians. Hypertension. 2015;66:865-73. DOI:10.1161/HYPERTENSIONAHA.115.05800.; Benetos A, Labat C, Rossignol P, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. 2015;175:989-95. DOI:10.1001/jamainternmed.2014.8012; Mossello E, Pieraccioli M, Nesti N, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med. 2015;175:578-85. DOI:10.1001/jamainternmed.2014.8164.; Streit S, Poortvliet RKE, Gussekloo J. Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old-data from the Leiden 85-plus Study. Age Ageing. 2018;47(4):545-50. DOI:10.1093/ageing/afy072.; Park SK, Park SK, Lee DY, et al. Comparing the clinical efficacy of resting and antihypertensive medication in patients of hypertensive urgency: a randomized, control trial. Journal of Hypertension. 2017;35:1474-80. DOI:10.1097/HJH.000000000000134.; van den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37-46. DOI:10.1093/ehjcvp/pvy032.; Peixoto AJ. Acute Severe Hypertension. N Engl J Med 2019;381:1843-52. DOI:10.1056/NEJMcp1901117.; Campos CL, Herring CT, Ali AN, et al. Pharmacologic Treatment of Hypertensive Urgency in the Outpatient Setting: A Systematic Review, J Gen Intern Med. 2018;33(4):539-50. DOI:10.1007/s11606-017-4277-6.; Ткачева О.Н., Котовская Ю.В., Ерусланова К.А. Гипертонический криз у лиц пожилого возраста. Кардиология. 2020;60(5):128-35. DOI:10.18087/cardio.2020.5.n1121.; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Клинические рекомендации «Старческая астения». Российский Журнал Гериатрической Медицины. 2020;(1):11-46. DOI:10.37586/2686-8636-1-2020-11-46.; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Клинические рекомендации «Старческая астения». Часть 2. Российский Журнал Гериатрической Медицины. 2020;(2):115-30. DOI:10.37586/2686-8636-2-2020-115-130.; Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98. DOI:10.1056/NEJMoa0801369; Williamson JD, Supiano MA, Applegate WB, et al.; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673-82. DOI:10.1001/jama.2016.7050.; Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. DOI:10.1186/s12916-015-0328-1.; Leung AA, Daskalopoulou SS, Dasgupta K, et al.; Hypertension Canada. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–576. DOI:10.1016/j.cjca.2017.03.005.; Whelton PK, Carey RM, Aronow WS, et a. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324. DOI:10.1161/HYP.0000000000000066.; Strandberg T, Benetos A. Successful SPRINT hypertension trial does not cover all older patients. Eur Geriatr Med. 2017;8:279-80.; Forette F, Seux M, Staessen J, et al. Prevention of dementia in a randomised double blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51. DOI:10.1016/s0140-6736(98)03086-4.; Lithell H, Hansson L, Skoog I, et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-86. DOI:10.1097/00004872-200305000-00011.; Saxby BK, Harrington F, Wesnes KA, et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008;70(19 Pt 2):1858-66. DOI:10.1212/01.wnl.0000311447.85948.78.; Lebouvier T, Chen Y, Duriez P, et al. Antihypertensive agents in Alzheimer's disease: beyond vascular protection. Expert Rev Neurother. 2020;20(2):175-87. DOI:10.1080/14737175.2020.1708195.; Peters R, Beckett N, Forette F, et al.; HYVET Investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683-9. DOI:10.1016/S1474-4422(08)70143-1.; SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553-61. DOI:10.1001/jama.2018.21442.; Williams B, Mancia G, Spiering W, et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. DOI:10.1097/HJH.0000000000001940.; Qaseem A, Wilt TJ, Rich R, et al.; Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017;166:430-7. DOI:10.7326/M16-1785.; Jones NR, McCormack T, Constanti M, McManus RJ Diagnosis and management of hypertension in adults: NICE guideline update 2019. British Journal of General Practice. 2020;70(691):90-1. DOI:10.3399/bjgp20X708053.; Kernick D. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract. 2017;67(658):235-6. DOI:10.3399/bjgp17X690857.; Артериальная гипертензия у взрослых. Клинические рекомендации [цитировано 12.04.2021]. Доступно на: http://cr.rosminzdrav.ru/recomend/62_1.; Pilotto A, Noale M, Maggi S, et al. Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients. Biomed Res Int. 2014;2014:906103. DOI:10.1155/2014/906103.; Butrous H, Hummel SL. Heart failure in older adults. Can J Cardiol. 2016;32:1140-7. DOI:10.1016/j.cjca.2016.05.005.; Stortecky S, Schoenenberger AW, Moser A, et al. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2012;5:489-96. DOI:10.1016/j.jcin.2012.02.012; Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56:1668-76. DOI:10.1016/j.jacc.2010.06.039.; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2016;37:2893-962. DOI:10.1093/eurheartj/ehw210.; Котовская Ю.В., Ткачева О.Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119-32. DOI:10.18087/cardio.2020.6.n1037.; Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28:237–53. DOI:10.1016/j.cger.2012.01.006.; Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021-31. DOI:10.2165/0002512-200825120-00004.; Sheppard JP, Burt J, Lown M, et al.; OPTIMISE Investigators. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020;323(20):2039-51. DOI:10.1001/jama.2020.4871.; Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376:1943-55. DOI:10.1056/NEJMoa1616338.; Sparling PB, Howard BJ, Dunstan DW, Owen N. Recommendations for physical activity in older adults. BMJ. 2015;350:h100. DOI:10.1136/bmj.h100.; Puttnam R, Davis BR, Pressel SL, et al. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. 2017;177(1):67-76. DOI:10.1001/jamainternmed.2016.6821.; Ekbom T, Linjer E, Hedner T, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP‐Hypertension‐2. Blood Pressure. 2004;13(3):137-41. DOI:10.1080/08037050410014944.; Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month Data on Blood Pressure and Tolerability. With Special Reference to Age and Gender. Blood Pressure. 1995;4(5):313- 9. DOI:10.3109/08037059509077613.; Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month Data on Blood Pressure and Tolerability. With Special Reference to Age and Gender. Blood Pressure. 1997;6(5):313- 7. DOI:10.3109/08037059709062088.; Schaefer RM, Aldons PM, Burgess ED, et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract. 1998;52(6):381-6.; Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017;8(4):155-65. DOI:10.4103/jpp.JPP_34_17.; Juraschek SP, Simpson LM, Davis BR, et al. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Hypertens. 2020;38(5):954-60. DOI:10.1097/HJH.0000000000002359.; Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17(11):781-5. DOI:10.1038/sj.jhh.1001613.; Malacco E, Varì N, Capuano V, et al.; Val-Syst study. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003;25(11):2765-80. DOI:10.1016/s0149-2918(03)80332-6.; Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559; Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372(9644):1174-83. DOI:10.1016/S0140-6736(08)61242-8.; Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. DOI:10.2165/00003495-200464090-00011.; Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging. 2009;26(1):61-76. DOI:10.2165/0002512-200926010-00005.; Malacco E, Omboni S, Mallion JM, Volpe M; ESPORT Study Group. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. High Blood Press Cardiovasc Prev. 2012;19(4):213-22. DOI:10.1007/BF03297633.; Omboni S, Malacco E, Mallion JM, Fabrizzi P, Volpe M. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. High Blood Press Cardiovasc Prev. 2014;21(1):1-19. DOI:10.1007/s40292-013-0037-9.; Takagi H, Mizuno Y, Niwa M, et al. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37(5):432-7. DOI:10.1038/hr.2013.142.; Wang JG, Zhang M, Feng YQ, Ma CS, Wang TD, Zhu ZM, Kario K. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2021;23(5):901-14. DOI:10.1111/jch.14227.; Kwon A, Kim GH. Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review. Clin Ther. 2020;42(7):1390-403. DOI:10.1016/j.clinthera.2020.05.015; Hanon O, Berrou JP, Negre-Pages L, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008;26(8):1642-50. DOI:10.1097/HJH.0b013e328301a280.; Laher MS, Mulkerrins E, Hosie J, et al. The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. J Hum Hypertens. 1991;5 Suppl 2: 77-8.; Langtry HD, Markham A. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 1997;10(2):131-66. DOI:10.2165/00002512-199710020-00006.; Malacco E, Piazza S, Omboni S; Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients : A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig. 2005;25(3):175-82. DOI:10.2165/00044011-200525030-00003.; Omboni S, Malacco E, Napoli C, et al. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies. Adv Ther. 2017;34(4):784- 98. DOI:10.1007/s12325-017-0497-8.; van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al.; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53(23):2150-8. DOI:10.1016/j.jacc.2009.02.046.; https://www.rpcardio.com/jour/article/view/2517
-
4Report
Θεματικοί όροι: пожилой возраст, cognitive functions, type 2 diabetes mellitus, elderly age, malnutrition, сахарный диабет 2 типа, comprehensive geriatric assessment, функциональная активность, hypoglycemia, комплексная гериатрическая оценка, мальнутриция, functional activity, когнитивные функции, гипогликемия
-
5Academic Journal
Συγγραφείς: Сакевич, Вікторія Дмитрівна, Трибрат, Тетяна Анатоліївна, Ляховська, Наталія Вячеславівна, Сакевич, Валентина Іванівна, Редчиць, Іван Васильович, Сакевич, Виктория Дмитриевна, Трибрат, Татьяна Анатольевна, Ляховская, Наталья Вячеславовна, Сакевич, Валентина Ивановна, Редчиц, Иван Васильевич, Sakevych, V. D., Trybrat, T. A., Liakhovska, N. V., Sakevych, V. I., Redchyts, I. V.
Θεματικοί όροι: комплексна геріатрична оцінка, гомеорез, похилий вік, компоненти комплексної геріатричної оцінки, здорове старіння, комплексная гериатрическая оценка, пожилой возраст, компоненты комплексной гериатрической оценки, здоровое старение, complex geriatric evaluation, homeoresis, old age, components of complex geriatric evaluation, healthy aging, УДК 616008.9:613.71/9
Περιγραφή αρχείου: application/pdf
Relation: Основи комплексної геріатричної оцінки. Гомеорез як предиктор функціонального статусу / В. Д. Сакевич, Т. А. Трибрат, Н. В. Ляховська [та ін.] // Вісник проблем біології і медицини. – 2019. – Вип. 4, т. 2 (154). – С. 41–47.; https://repository.pdmu.edu.ua/handle/123456789/12501
-
6Academic Journal
Συγγραφείς: L. M. Farkhutdinova, Л. М. Фархутдинова
Πηγή: The Russian Archives of Internal Medicine; Том 9, № 4 (2019); 245-252 ; Архивъ внутренней медицины; Том 9, № 4 (2019); 245-252 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-9-4
Θεματικοί όροι: старческая астения, comprehensive geriatric assessment, senile asthenia, комплексная гериатрическая оценка
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/944/812; https://www.medarhive.ru/jour/article/view/944/823; Аммосова Е.Е. Комплексная гериатрическая оценка в условиях дома-интерната. Российский семейный врач. 2018; 22(2): 25–29. Ammosova Е.Е. Comprehensive geriatric evaluation in boarding house conditions. Russian family doctor. 2018; 22 (2): 25-29. [In Russian]; Актуальные проблемы геронтологии и гериатрии: монография /под ред. В.П. Волкова. Новосибирск: Изд. «СиБАК». 2015; 138 с. Actual problems of gerontology and geriatrics: monograph /ed. by V.P. Volkov. Novosibirsk: Publishing «SiBAK». 2015; 138 р. [In Russian]; Кирщина И.А., Габдрафикова Ю.С. Характеристика полиморбидных состояний и оценка полипрагмации у женщин в гериатрической практике. Сибирский медицинский журнал (Иркутск). 2014; 8: 67–70. Kirshchina I.A., Gabdrafikova Yu.S. Characteristics of polymorbid conditions and evaluation of polypragmentation in women in geriatric practice. Siberian Medical Journal (Irkutsk). 2014; 8: 67–70. [In Russian]; Киселева Г.В., Фролова Е.В., Турушева А.В. Выявление пожилых людей с высоким риском падения с помощью комплексной гериатрической оценки. Лечащий врач. 2019; 1: 66–70. Kiseleva G.V., Frolova Е.V., Turusheva A.V. Revealing older people at high risk of falling with a comprehensive geriatric assessment. Attending doctor. 2019; 1: 66–70. [In Russian]; Козлов С.Е., Кирщина И.А., Габдрафикова Ю.С. Солонинина А.В. Рациональные комбинации лекарственных препаратов при лечении сосудистой патологии в гериатрии. Клиническая медицина. 2015; 11: 54–59. Kozlov S.Е., Kirshchina I.A., Gabdrafikova YU.S. Soloninina A.V. Rational drug combinations in the treatment of vascular pathology in geriatrics. Clinical medicine. 2015; 11: 54–59. [In Russian]; Куличенко Л.Л., Ивахненко И.В. Характеристика соматической патологии у людей пожилого и старческого возраста. Волгоградский научно-медицинский журнал. 2012; 1: 88–89. Kulichenko L.L., Ivahnenko I.V. Characteristics of somatic pathology in the elderly and senile age. Volgograd Scientific Medical Journal. 2012; 1: 88–89. [In Russian]; Руководство по геронтологии и гериатрии: в 4 т. /под ред. акад. РАМН, проф. В.Н. Ярыгина, проф. А.С. Мелентьева. М.: ГЭОТАР-Медиа, 2010; Т. 3. Клиническая гериатрия. 896 с. Manual to gerontology and geriatrics: 4 v. /Ed. acad. RAMS, prof. V.N. Yarygin, prof. A.S. Melentyeva. M.: GEOTAR-Media, 2010; V. 3. Clinical geriatrics. 896 p. [In Russian]; Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. СПб.: ЦОП «Профессия». 2016; 224 с. Sychev D.A. Polyparmacy in clinical practice: a problem and solutions. St. Petersburg: CSC «Profession». 2016; 224 р. [In Russian]; Ткачева О.Н. современная концепция развития гериатрической помощи в Российской Федерации. Вестник Росздравнадзора. 2016; 4: 31–35. Tkacheva O.N. The modern concept of the development of geriatric care in the Russian Federation. Bulletin of Roszdravnadzor. 2016; 4: 31–35. [In Russian]; Турушева А.В., Фролова Е.В., Дегриз Ж.М. Эволюция теории старческой астении. Вестник Северо-Западного государственного медицинского университета. 2017; 9(1): 117–124. Turusheva A.V., Frolova E.V., Degriz Z.M. The evolution of the theory of senile asthenia. Bulletin of Northwestern State Medical University. 2017; 9 (1): 117–124. [In Russian]; Фархутдинова Л.М. Диффузный токсический зоб. Уфа: Гилем. 2012; 140 с. Farhutdinova L.M. Diffuse toxic goiter. Ufa: Gilem. 2012; 140 р. [In Russian]; Фархутдинова Л.М. Первичный гиперпаратиреоз: проблемы и пути решения. Медицинский вестник Башкортостана. 2010; 5(1): 65–70. Farhutdinova L.M. Primary hyperparathyroidism: problems and solutions. Medical Bulletin of Bashkortostan. 2010; 5 (1): 65–70. [In Russian]; Шабалин В.Н. Организация работы гериатрической службы в условиях прогрессирующего демографического старения населения Российской Федерации. Успехи геронтологии. 2009; 22(1): 185–195. Shabalin V.N. Organization of work of the geriatric service in the conditions of progressive demographic aging of the population of the Russian Federation. Successes of gerontology. 2009; 22(1): 185–195. [In Russian]; Iseli R., Nguyen V., Reijnierse E. et al. Orthostatic hypotension and its association with cognitive impairment in older adults: a systematic review and meta-analysis. Ageing Research Reviews. 2018; 48: 122–144.; Kojima G. Prevalence of Frailty in nursing homes: a systematic review and metaanalysis. J Am Med Dir Assoc. 2015; 16: 940–945.; Press Y., Biderman A., Peleg R. et al. Benefits of active participation of family physicians in geriatric consultations. Geriatr Gerontol Int. 2012; 12 (4): 725–732.; Schluter P.J., Arnold E.P., Jamieson H.A. Falls and hip fractures associated with urinary incontinence among older men and women with complex needs: a national population study. Neurourol Urodyn. 2018; 37(4): 1336–1343.; Vaughan L., Corbin A.L., Goveas J.S. Depression and frailty in later life: a systematic revier. Clin Interv Aging. 2015; 10: 1947–58.; https://www.medarhive.ru/jour/article/view/944
-
7Academic Journal
Συγγραφείς: O. A. Koroleva, L. M. Kogoniya, M. M. Byakhova, A. G. Titov, О. А. Королева, Л. М. Когония, М. М. Бяхова, А. Г. Титов
Πηγή: Malignant tumours; Том 8, № 2 (2018); 64-75 ; Злокачественные опухоли; Том 8, № 2 (2018); 64-75 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: паллиативная терапия, chemotherapy, complex geriatric evaluation, adjuvant therapy, palliative therapy, химиотерапия, комплексная гериатрическая оценка, адъювантная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/518/372; Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015. Vol. 136. P. E359–86.; GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr.; Parkin D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 2006. Vol. 118. P. 3030–3044.; Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014. Vol. 64. P. 9–29.; Статистика злокачественных новообразований в России и странах СНГ в 2013 г. / под ред. Давыдова М. И., Аксель Е. М. Москва, 2015.; Glimelius B., Ekstrom K., Hoffman K., Graf W., Sjoden P. O., Haglund U. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997. Vol. 8. P. 163–168.; Pyrhonen S., Kuitunen T., Nyandoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer. 1995. Vol. 71. P. 587–591.; Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993. Vol. 72. P. 37–41.; Polee M. B., Hop W. C., Kok T. C., Eskens F. A., van der Burg M. E., Splinter T. A. et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br. J. Cancer. 2003. Vol. 89. P. 2045–2050.; Chau I., Norman A. R., Cunningham D., Waters J. S., Oates J., Ross P. J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 2004. Vol. 22. P. 2395–2403.; Trumper M., Ross P. J., Cunningham D., Norman A. R., Hawkins R., Seymour M. et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur. J. Cancer. 2006. Vol. 42. P. 827–834.; Jatoi A., Foster N. R., Egner J. R., Burch P. A., Stella P. J., Rubin J. et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int. J. Oncol. 2010. Vol. 36. P. 601–606.; Hurria A., Lichtman S. M. Clinical pharmacology of cancer therapies in older adults. Br. J. Cancer. 2008. Vol. 98. P. 517–522.; Repetto L., Fratino L., Audisio R. A., Venturino A., Gianni W., Vercelli M. et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J. Clin. Oncol. 2002. Vol. 20. P. 494–502.; Wedding U., Kodding D., Pientka L., Steinmetz H. T., Schmitz S. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit. Rev. Oncol. Hematol. 2007. Vol. 64. P. 1–9.; Extermann M., Aapro M., Bernabei R., Cohen H. J., Droz J. P., Lichtman S. et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 2005. Vol. 55. P. 241–252.; Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J. Clin. Oncol. 2007. Vol. 25. P. 1824–1831.; Pal S. K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J. Clin. 2010. Vol. 60. P. 120–132.; Rodin M. B., Mohile S. G. A practical approach to geriatric assessment in oncology. J. Clin. Oncol. 2007. Vol. 25. P. 1936–1944.; Hurria A., Gupta S., Zauderer M., Zuckerman E. L., Cohen H. J., Muss H. et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005. Vol. 104. P. 1998–2005.; Hurria A., Cirrincione C. T., Muss H. B., Kornblith A. B., Barry W., Artz A. S. et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J. Clin. Oncol. 2011. Vol. 29. P. 1290–1296.; Hurria A., Togawa K., Mohile S. G., Owusu C., Klepin H. D., Gross C. P. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 2011. Vol. 29. P. 3457–3465.; Cunningham D., Allum W. H., Stenning S. P., Thompson J. N., Van de Velde C. J., Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006. Vol. 355. P. 11–20.; Ychou M., Boige V., Pignon J. P., Conroy T., Bouche O., Lebreton G. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011. Vol. 29. P. 1715–1721.; Xiong B. H., Cheng Y., Ma L., Zhang C. Q. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest. 2014. Vol. 32. P. 272–284.; Kulig J., Kolodziejczyk P., Sierzega M., Bobrzynski L., Jedrys J., Popiela T. et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010. Vol. 78. P. 54–61.; Bouche O., Ychou M., Burtin P., Bedenne L., Ducreux M., Lebreton G. et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann. Oncol. 2005. Vol. 16. P. 1488–1497.; Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007. Vol. 357. P. 1810–1820.; Bang Y. J., Kim Y. W., Yang H. K., Chung H. C., Park Y. K., Lee K. H. et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012. Vol. 379. P. 315–321.; Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011. Vol. 29. P. 4387–4393.; Noh S. H., Park S. R., Yang H. K., Chung H. C., Chung I. J., Kim S. W. et al. CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Lancet Oncol. 2014. Vol. 15. P. 1389–1396.; Wagner A. D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., Fleig W. E. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 2010. CD004064.; Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K. et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 1997. Vol. 5. P. 261–267.; Kim N. K., Park Y. S., Heo D. S., Suh C., Kim S. Y., Park K. C. et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993. Vol. 71. P. 3813–3818.; Ohtsu A., Shimada Y., Shirao K., Boku N., Hyodo I., Saito H. et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 2003. Vol. 21. P. 54–59.; Lord S. R., Hall P. S., McShane P., Brown J., Seymour M. T. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin. Oncol. 2010. Vol. 22. P. 107–113.; Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F. et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008. Vol. 358. P. 36–46.; Al-Batran S. E., Hartmann J. T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 2008. Vol. 26. P. 1435–1442.; Santini D., Graziano F., Catalano V., Di Seri M., Testa E., Baldelli A. M. et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 2006. Vol. 6. P. 125–131.; Choi I. S., Oh D. Y., Kim B. S., Lee K. W., Kim J. H., Lee J. S. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res. Treat. 2007. Vol. 39. P. 99–103.; Liu Z. F., Guo Q. S., Zhang X. Q., Yang X. G., Guan F., Fu Z., Wang M. Y. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am. J. Clin. Oncol. 2008. Vol. 31. P. 259–263.; Dong N., Jiang W., Li H., Liu Z., Xu X., Wang M. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am. J. Clin. Oncol. 2009. Vol. 32. P. 559–563.; Zhao J. G., Qiu F., Xiong J. P., Zhang L., Xiang X. J., Yu F. et al. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs. 2009. Vol. 20. P. 281–286.; Xiang X. J., Zhang L., Qiu F., Yu F., Zhan Z. Y., Feng M. et al. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy. 2012. Vol. 58. P. 1–7.; Catalano V., Bisonni R., Graziano F., Giordani P., Alessandroni P., Baldelli A. M. et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013. Vol. 16. P. 411–419.; Nardi M., Azzarello D., Maisano R., Del Medico P., Giannicola R., Raffaele M. et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J. Chemother. 2007. Vol. 19. P. 85–89.; Kim H. S., Kim J. H., Kim H. J., Jang H. J., Kim J. B., Kim J. W. et al. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol. Lett. 2012. Vol. 3. P. 425–428.; Cho Y. H., Kim S. Y., Hong Lee M., Yoo M. W., Bang H. Y., Lee K. Y., Yoon S. Y. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil / leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Gastric Cancer. 2012. Vol. 15. P. 389–395.; Al-Batran S. E., Pauligk C., Homann N., Hartmann J. T., Moehler M., Probst S. et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur. J. Cancer. 2013. Vol. 49. P. 835–842.; Kang Y. K., Kang W. K., Shin D. B., Chen J., Xiong J., Wang J. et al. Capecitabine / cisplatin versus 5-fluorouracil / cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann. Oncol. 2009. Vol. 20. P. 666–673.; Okines A. F., Norman A. R., McCloud P., Kang Y. K., Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol. 2009. Vol. 20. P. 1529–1534.; Boku N., Yamamoto S., Fukuda H., Shirao K., Doi T., Sawaki A. et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009. Vol. 10. P. 1063–1069.; Ajani J. A., Rodriguez W., Bodoky G., Moiseyenko V., Lichinitser M., Gorbunova V. et al. Multicenter phase III comparison of cisplatin / S-1 with cisplatin / infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 2010. Vol. 28. P. 1547–1553.; Lee J. L., Kang Y. K., Kang H. J., Lee K. H., Zang D. Y., Ryoo B. Y. et al. A randomized multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer. 2008. Vol. 99. P. 584–590; Hwang I. G., Lee H. R., Lee H. Y., Ji J. H., Kang J. H., Lee S. I. et al. First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis. J. Clin. Oncol. 2015. Vol. 33 (suppl). abstr4051.; Koizumi W., Akiya T., Sato A., Sakuyama T., Sasaki E., Tomidokoro T. et al. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother. Pharmacol. 2010. Vol. 65. P. 1093–1099.; Petrioli R., Pascucci A., Francini E., Marsili S., Fiaschi A. I., Civitelli S. et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008. Vol. 19. P. 91–96.; Bang Y. J., Van Cutsem E., Feyereislova A., Chung H. C., Shen L., Sawaki A. et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010. Vol. 376. P. 687–697.; Fuchs C. S., Tomasek J., Yong C. J., Dumitru F., Passalacqua R., Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet. 2014. Vol. 383. P. 31–39.; Wilke H., Muro K., Van Cutsem E., Oh S. C., Bodoky G., Shimada Y. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014. Vol. 15. P. 1224–1235.; Van Cutsem E., Moiseyenko V. M., Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 2006. Vol. 24. P. 4991–4997.; Ajani J. A., Moiseyenko V. M., Tjulandin S. et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J. Clin. Oncol. 2007. Vol. 25. P. 3210–3216.; Ilson D. H. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J. Clin. Oncol. 2007. Vol. 25 (22). P. 3188–3190.; Cunningham D., Starling N., Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008. Vol. 358 (1). P. 36–46.; https://www.malignanttumors.org/jour/article/view/518
-
8
-
9Academic Journal
Συγγραφείς: ДЕГРИЗ Я.-М., ФРОЛОВА Е.В., ТУР Е.Ю.
Περιγραφή αρχείου: text/html
-
10Academic Journal
Συγγραφείς: КУЗНЕЦОВА О.Ю., ФРОЛОВА Е.В., ЯКОВЛЕВ И.А.
Θεματικοί όροι:
ГЕРИАТРИЯ,GERIATRICS,FRAILTY,ОБЩАЯ ВРАЧЕБНАЯ ПРАКТИКА,GENERAL PRACTICE,КОМПЛЕКСНАЯ ГЕРИАТРИЧЕСКАЯ ОЦЕНКА,COMPREHENSIVE GERIATRIC ASSESSMENT,ПРОЕКТ "ХРУСТАЛЬ",THE "CRYSTAL" PROJECT,ШКОЛА ДЛЯ ПРЕПОДАВАТЕЛЕЙ,TEACHING SCHOOL,ХРУПКОСТЬ Περιγραφή αρχείου: text/html
-
11
-
12Academic Journal
Πηγή: Российский семейный врач.
Θεματικοί όροι: 3. Good health, КОМПЛЕКСНАЯ ГЕРИАТРИЧЕСКАЯ ОЦЕНКА,COMPREHENSIVE GERIATRIC ASSESSMENT,НЕУДОВЛЕТВОРЕННЫЕ ПОТРЕБНОСТИ ПОЖИЛЫХ И СТАРЫХ ПАЦИЕНТОВ,UNMET NEEDS OF THE ELDERLY AND OLD PATIENTS,WEB BASED APPROACH,FRAILTY,ВЕБ-ПРИЛОЖЕНИЕ,ХРУПКОСТЬ
Περιγραφή αρχείου: text/html
-
13Academic Journal
Πηγή: Российский семейный врач.
Περιγραφή αρχείου: text/html
-
14
-
15Report
Θεματικοί όροι: older generation, старческий возраст, elderly age, пациент, medical and social care, social protection, старческая астения, 3. Good health, комплексная гериатрическая оценка, complex geriatric assessment, социальная защита, medical organiza- tion, пожилой возраст, patient, старшее поколение, senile age, медицинская организация, медико-социальная помощь, senile asthenia
-
16
-
17Academic Journal
Συγγραφείς: Ткачева О.Н., Котовская Ю.В., Остапенко В.С., Шарашкина Н.В.
Πηγή: РМЖ
Θεματικοί όροι: старческая астения,
"хрупкость", пожилые, старение, комплексная гериатрическая оценка, скрининг Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/146794/
